Correlating Expression of NaPi2b and Folate Receptor Alpha (FRα) in High-Grade Serous Ovarian Cancer (HGSO)

Debra L. Richardson, Minal A. Barve, Erika P. Hamilton, Sara Kristina Taylor, Charles K. Anderson, Joseph Buscema, Marilyn Huang, Rebecca Christian Arend, John L. Hays, Premal H. Thaker, Nehal J. Lakhani, Pamela Shaw, Chadshaw, Min Lu

BACKGROUND

- Platinum-resistant ovarian cancer (PROC) is marked by a high unmet medical need, with single-agent chemotherapy as the SOC providing an ORR of ≈12%.
- Most ovarian tumors that respond to frontline treatment recur and eventually become platinum resistant.
- There are few treatment options currently available for patients with PROC and for most patients, the clinical outcome is poor.
- Biomarker-driven therapies are increasingly being utilized and studied for potential use in gynecologic cancers, including PROC.

METHODS

- Sample Collection: Tumor samples were obtained from 84 patients from the UpRi Phase 1b expansion (EXP) study (NCT03319628).
- For patients with both archival and fresh tumor samples, only archival data were included as prior studies suggest concordance between archival and fresh tissue.

RESULTS

- NaPi2b and FRα RNA Expression Correlation Analysis
  - 21% (n=18) of samples had both NaPi2b-positive and FRα-positive RNA expression (by Nanostring).
  - 32% (n=27) of samples had both NaPi2b-negative and FRα-negative RNA expression (by Nanostring).
  - No statistically significant association was observed (Chi-squared test, P=0.129).

- NaPi2b and FRα RNA Expression Correlation Analysis
  - 12% (14) of samples had both NaPi2b-positive and FRα-positive RNA expression (by Nanostring).
  - 12% (14) of samples had both NaPi2b-negative and FRα-negative RNA expression (by Nanostring).
  - A correlation analysis was performed to assess the overlap between NaPi2b and FRα RNA expression.

ACKNOWLEDGMENTS

We would like to thank the patients, their families, and the site staff for making this study possible.

REFERENCES

3. Roche. VENTANA FOLR1 (FOLR‑2.1) RxDx Assay. USPI. 2022.